February Newsmakers

The Financial Toxicity of Illness (The New York Times)
Features Yousuf Zafar, MD, MHS

Better breast cancer screening, treatments may have saved hundreds of thousands of lives over 30 years (Reuters)
Features Jay Baker, MD

Duke recreational therapist goes above and beyond for cancer patients (WNCN)
Features Tiffany Atkinson, MS, LRT-CTRS

Colon Cancer Screening Controversy. Here's What All The Debate Is About (Forbes)
Features Peter Ubel, MD

Doctors share cancer screening information (The Wilson Times)
Features Betty Tong, MD; Tian Zhang, MD

Sunday Salute: Ashley Linden dealt with cancer by helping others (Fayetteville Observer)
Features Duke Cancer patient and DCI blog

Safety Of Flame Retardants Called Into Question (WCAI)
Features Kate Hoffman, PhD

Frederick National Laboratory, Duke partner to fight brain cancer (The Frederick News Post)
Features Matthias Gromeier, PhD

Overcoming the Immunosuppressive Tumor Microenvironment in Metastatic Pancreatic Cancer (Expert Perspectives in Metastatic Pancreatic Cancer)
Features Michael Morse, MD, MHS

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer (Uro Today)
Features Andrew Armstrong, MD

WATCH: 2019 Genitourinary Cancers Symposium / ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC (eCancer)
Features Andrew Armstrong, MD

Racial Disparities in Prostate Cancer Treatment and Outcomes - Susan Halabi (Uro Today)
Features Susan Halabi, PhD

Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer (OncLive)
Features Andrew Armstrong, MD

Hormonal Agents Induce Improved OS in African Americans With Chemo-Naive mCRPC (OncLive)
Features Megan McNamara, MD

WATCH: Prostate Cancer Disparities in the VA Health System - Megan McNamara (Uro Today)
Features Megan McNamara, MD

Romiplostim Classification and Mechanism of Action (OncLive)
Features Ivy Altomare, MD

Up-front Therapy With Carfilzomib in Myeloma (OncLive)
Cristina Gasparetto, MD

Further Evidence Needed Supporting Clinical Utility of Liquid Biopsies in GI Cancers (OncLive)
Features John Strickler, MD

WATCH: The Importance Of Genomic Profiling In Treating Colorectal Cancer (Oncology YouTube)
Features John Strickler, MD

Differences in Treatment Facilities, Histology Account for Survival Disparities in NSCLC (Targeted Oncology)
Features Jeffrey Crawford, MD

A Look at Therapy Toxicities & Biology in Head & Neck Cancers (Oncology Times)
Features Yvonne Mowery, MD, PhD

Do all chemotherapies have equal long-term heart risk? (Science Daily)
Features Kevin Oeffinger, MD

Cancer Patients 10 Times Less Likely To Die From Overdose (Clinical Oncology News)
Features Fumiko Chino, MD

With Blue Cross grant, Duke taps patient partnership app to take on opioid abuse (Mobi Health News)
Features Arif Kamal, MD

Coping With the Emotional Side Effects of AML (Patient Empowerment Network)
Features Thomas LeBlanc, MD 

Why Integrative Care? (Integrative Cancer Review)
Features Duke Medicine

WATCH: Dr. Brander shared her message with us in honor of World Cancer Day. What would you want to say to experts changing the treatment paradigm for CLL or other cancers? (Targeted Oncology/Twitter video)
Features Danielle Brander, MD

2019 Edward Novitski Prize awarded to Joseph Heitman (Duke University School of Medicine)
Joseph Heitman, MD, PhD 

A line of promising cancer drugs mysteriously failed in the 90s. Duke researchers may now know why (The Chronicle)
Features Laura Kelly, PhD

Brain Tumor 'Pied Piper' Device Gains Breakthrough Status (Pratt School of Engineering)
Features Ravi Bellamkonda, PhD

'Accidental discoveries': Cancer medications may have other uses (The Chronicle)
Features Ann Marie Pendergast, PhD

Newly Recruited Faculty Bring Expertise in Key Research Areas (Duke University School of Medicine)
Features Andrew West, PhD

Nurses turn end of treatment into a party for pediatric patients (Duke Department of Pediatrics)

Light and Sound Gauge the Temperature of Deep Tissues (Pratt School of Engineering)
Junjie Yao, PhD

Using Supercomputers to Checkmate Cancer (Duke OLV)
Features Marcel Frankel and Bruce Donald, PhD

EMGS Announces the 2019 Alexander Hollaender Award (EMGS)
Features Randy L. Jirtle, PhD, who directed the epigenetics and imprinting laboratory at Duke University until 2012

PAPERS

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Journal of Clinical Oncology. February 20, 2019. Neal Ready, MD, PhD; Matthew D. Hellmann, MD; Mark M. Awad, MD, PhD; Gregory A. Otterson, MD; Martin Gutierrez, MD; Justin F. Gainor, MD; Hossein Borghaei, D7; Jacques Jolivet, MD; Leora Horn, MD; Mihaela Mates, MD; Julie Brahmer, MD; Ian Rabinowitz, MD; Pavan S. Reddy, MD; Jason Chesney, MD, PhD; James Orcutt, MD; David R. Spigel, MD; Martin Reck, PhD; Kenneth John O’Byrne, MD; Luis Paz-Ares, MD, PhD; Wenhua Hu, PhD; Kim Zerba, PhD; Xuemei Li, MD; Brian Lestini, MD, PhD; William J. Geese, PhD; Joseph D. Szustakowski, PhD; George Green, PhD; Han Chang, PhD; and Suresh S. Ramalingam, MD. 

A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. Annals of Surgery. January 2019. Yang, Chi-Fu Jeffrey, MD; Kumar, Arvind, BS; Klapper, Jacob A., MD; Hartwig, Matthew G., MD, MHS; Tong, Betty C., MD, MHS; Harpole, David H. Jr., MD; Berry, Mark F., MD, MHS; D’Amico, Thomas A., MD.

Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncology. January 31, 2019.  Elizabeth A. M. Feijen, PhD; Wendy M. Leisenring, ScD; Kayla L. Stratton, MS; Kirsten K. Ness, PT, PhD; Helena J. H. van der Pal, MD, PhD; Elvira C. van Dalen, MD, PhD1; Gregory T. Armstrong, MD, MSCE; Gregory J. Aune, MD, PhD; Daniel M. Green, MD; Melissa M. Hudson, MD; Jacqueline Loonen, MD, PhD; Kevin C. Oeffinger, MD; Leslie L. Robison, PhD; Yutaka Yasui, PhD; Leontien C. M. Kremer, MD, PhD; Eric J. Chow, MD, MPH.

N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway. Molecular Cancer. January 2019. Yu Yin, Lingfan Xu, Yan Chang, Tao Zeng, Xufeng Chen, Aifeng Wang, Jeff Groth, Wen-Chi Foo, Chaozhao LiangEmail author, Hailiang HuEmail author and Jiaoti Huang.